Kaplan-Meier plots. (A) DOR with zanubrutinib treatment per IRC assessment for patients with MZL. (B) PFS with zanubrutinib per IRC assessment for patients with MZL. (C) DOR with zanubrutinib per investigator assessment for patients with FL. (D) PFS with zanubrutinib per investigator assessment for patients with FL.